ESPA-BASTIN®: a secret of successful and safe therapy of allergic diseases


DOI: https://dx.doi.org/10.18565/therapy.2019.2.129-135

Latysheva E.A., Manto I.A.

Institute of Immunology of FMBA of Russia, Moscow
More than 80 years have passed since the pioneering research of Anna Marie Staub and Daniel Bove in 1937 leading to the discovery of the first antihistamine drug. However, the pioneer drug was too toxic, so a few more years passed before the introduction of the 1st generation of H1-blockers into clinical practice in the 40s years of twentieth century. However, these drugs also showed significant side effects associated, firstly, with non-selectivity of action, and, secondly, with the penetration of drugs through the blood-brain barrier (BBB). Further, clinical pharmacology followed the path of creating antihistamines, having not only greater efficacy, but also a high safety profile by eliminating failures typical for the 1st generation medicaments. This led to the appearance in 1980s the H1-blockers of 2nd generation. In addition to the strength of the molecule, the competitive advantage of a drug is formed by such characteristics as the rate of start of the clinical effect, duration of action, frequency of use, safety and tolerability, which can significantly vary among medicaments from different manufacturers. A modern molecule from the group H1-blockers of the 2nd generation with one of the best indicators on the above criteria is Ebastine, which has proven its effectiveness and safety in numerous studies performed in accordance with GMP and GCP standards. For 30 years, more than 80 countries around the world have accumulated a huge positive clinical experience concerning the use of this medicine. Ebastine is an active substance of a high-quality German ESPA-BASTIN® medicine.
Keywords: antihistamine medicaments, ESPA-BASTIN®, urticaria, histamine, ebastine, allergic rhinitis
Read entire article

Literature


  1. Cezmi A. Akdis, Ioana Agache. Global Atlas of Allergy. European Academy of Allergy and Clinical Immunology. 2014: 39–179.

  2. Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct; 140(4): 950–58. doi: 10.1016/j.jaci.2017.03.050.

  3. Рёкен М., Греверс Г., Бургдорф В. Наглядная Аллергология. Москва. БИНОМ. Лаборатория знаний. 2008: 34–105.

  4. Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008 Dec; 63 Suppl 89: 1–20. doi: 10.1111/j.1398-9995.2008.01897.x.

  5. Church D.S., Church M.K. Pharmacology of antihistamines. World Allergy Organ J. 2011 Mar; 4(3 Suppl): S22–27. doi: 10.1097/WOX.0b013e3181f385d9.

  6. Church D.S., Church M.K. Pharmacology of antihistamines. Indian J Dermatol. 2013 May-Jun; 58(3): 219–24. doi: 10.4103/0019-5154.110832.

  7. Аллергология и иммунология. Национальное руководство, краткое издание под ред. акад. РАН и РАМН Р.М. Хаитова, проф. Н.И. Ильиной. М.: ГЭОТАР-Медиа. 2013: 88–411.

  8. Zuberbier T., Aberer W., Asero R., Abdul Latiff A.H., Baker D., Ballmer-Weber et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 Jul; 73(7): 1393–414. doi: 10.1111/all.13397.

  9. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog Neurobiol. 2001 Apr; 63(6): 637–72.

  10. ЭСПА-БАСТИН®. Инструкция по медицинскому применению препарата. ЛП-003460.

  11. Simons F.E. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002 Dec 16; 113 Suppl 9A: 38S–46S.

  12. Wiseman L.R., Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 1996 Feb; 51(2): 260–77.

  13. Frossard N., Vital-Durand D., Mounedji N., Valleteau A. Duration of the antihistaminic effect after discontinuation of ebastine. Allergy. 2001 Jun; 56(6): 553–57.

  14. Rohatagi S., Gillen M., Aubeneau M., Jan C., Pandit B., Jensen B.K. et al. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther. 2001; 39: 126–34.

  15. Lasseter K.C., Dilzer S.C., Vargas R., Waldman S., Noveck R.J. Pharmacokineticsand safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokine.t 2004; 43: 121–29.

  16. de Molina M., Cadahia A., Cano L., Sanz A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest. 1989; 1: 40–46.

  17. Pelaez A. Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. Drugs. 1996; 52(Suppl.1): 35–38.

  18. Storms W.W. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs. 1996; 52(Suppl. 1): 20–25.

  19. Gehanno P., Bremard-Oury C., Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol. 1996; 76: 507–12.

  20. Hampel F., Howland W., van Bavel J., Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004; 14: 56–63.

  21. Ratner P., Hampel F., van Bavel J., Howland W. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol. 2004; 133: 371–79.

  22. Ratner P.H., Lim J.C., Georges G.C. Ebastine Study Group. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol. 2000; 105(6 Pt 1): 1101–07.

  23. Bousquet J., Gaudano E.M., Palma Carlos A.G., Staudinger H. A 12-week, placebocontrolled study of the efficay and safety of ebastine 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Allergy. 1999; 54: 562–68.

  24. Davies R.J. European Multicentre Study Group. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomized study in patients with perennial allergic rhinitis. Clin Drug Invest. 1998; 16: 413–20.

  25. Murris-Espin M., Melac M., Charpentier J-C., Didier A. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998; 80: 399–403.

  26. Peyri J., Vidal J., Marron J., Fonseca E., Suarez E., Ledo A. et al. Ebastine in chronic urticaria: a double-blind placebo- controlled study. J Dermatol Treat. 1991; 2: 51–53.

  27. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996; 52(Suppl. 1): 30–34.

  28. Magerl M., Schmolke J., Siebenhaar F., Zuberbier T., Metz M., Maurer M. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy. 2007; 62: 1465–68.

  29. Magerl M., Schmolke J., Siebenhaar F., Zuberbier T., Metz M., Maurer M. Dermographic urticaria symptoms can be safely prevented by ebastine (abstract plus poster). XX World Allergy Congress. 2007, Dec 2–6, Bangkok.

  30. Wood-Baker R., Holgate S.T. Dose-response relationship of the H1-histamineantagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents Action. 1990; 30: 284–86.

  31. Horiguchi T., Tachikawa S., Kasahara J., Shiga M., Kondo R., Miyazaki J. et al. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest. 1999; 17: 435–40.

  32. Karpinnen A., Petman L., Jukunen A., Kautiainen H., Vaalasti A., Reunala T. Treatment of mosquito bites with ebastine: a field trial. Acta Derm Venereol. 2000; 80: 114–16.

  33. Robert M., Llorens M., Garcia E., Luria X., Common Cold Collaborative Group. Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. Eur J Int Med. 2004; 15: 242–47.

  34. Moss A.J., Chaikin P., Garcia J.D., Gillen M., Roberts D.J., Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999; 29(Suppl. 3): 200–05.

  35. Huang M-Y., Argenti D., Wilson J., Garcia J., Heald D. Pharmacokinetics and electrocardiographic effect of ebastine in young vs elderly healthy subjects. Am J Ther 1998; 5: 153–58.

  36. Gillen M.S., Miller B., Chaikin P., Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol. 2001; 52: 201–04.

  37. Gispert J., Esbri R., Garcia E. et al. Ebastine has no effect on QTc interval at doses up to 50 times the therapeutic dose [abstract 779]. Allergy. 2002; 57(Suppl. 73): 243–44.


About the Autors

Elena A. Latysheva, PhD, associate professor of the Department of clinical immunology of N.I. Pirogov Russian National Research medical University, senior research scientist of the Department of immunopathology of the Clinic of the Institute of immunology of FMBA of Russia. Address: 115478, Moscow, 24 Kashirskoye shosse Str.
Tel.: +7 (968) 867-10-64. E-mail: ealat@mail.ru
Irina A. Manto, junior researcher of the Department of immunopathology of adults of the Clinic of the Institute of immunology of FMBA of Russia. Address: 115478, Moscow, 24 Kashirskoye shosse Str. Tel.: +7 (985)146-23-21.
E-mail: irina.manto@yandex.ru


Similar Articles

Back to Content

Бионика Медиа